Navigation Links
Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
Date:6/30/2011

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 – 7, 2011, in Amsterdam, The Netherlands.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-151MM-151 is designed to effectively block downstream signaling of the EGFR receptor, a key oncogene in various carcinomas. The poster will present pre-clinical data regarding the potency of MM-151 compared to existing monoclonal therapies targeting EGFR.Poster #3656 presents preclinical data on the ability of  MM-151 to effectively block EGFR pathway activation in in-vitro signaling and inhibit tumor cell growth in-vitro and in-vivo in lung cancer modelsPoster Session:  P2.070: Poster Session 2

Number:  3656

Date/Time:  Tuesday, July 5, from 12:15 PM – 2:00 PM

Location:  RAI Exhibition and Convention Centre, Exhibition HallMM-398  

MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors.  MM-398, in partnership with PharmaEngine, Inc., is in clinical development in colorectal, gastric and pancreatic cancer and in glioma.  The poster will present preclinical data on the safety and activity of MM-398 in lung cancer xenograft models.Poster #S420-421 presents preclinical data on MM-398's safety and activity Oral Session:  033.03: Preclinical Models 1

Number:  S420-421

Date/Time:  Wednesday, July 6, from 2:30 PM – 4:00 PM

Location:  Room D201About Merrimack Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer. Merrimack is advancing a pipeline of engineered therapeutics paired with molecular diagnostics. In addition to several pre-clinical and research-stage programs, Merrimack has five oncology candidates in clinical development or expected to enter clinical development this year: MM-398, in Phase 2 testing in partnership with PharmaEngine, Inc., MM-121, in Phase 2 testing in partnership with Sanofi, MM-111 in Phase 1 / 2 testing; and MM-302 and MM-151, which are both expected to enter Phase 1 clinical development this year. MM-398, MM-121, MM-111, MM-302 and MM-151 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Merrimack uses its proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, to integrate the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutic s and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact:  Rachel Yaroschuk, Corporate Communications, Merrimack, 617-441-7414  
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
2. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
3. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
4. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
6. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
7. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
8. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
9. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
11. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers ... a new way to treat the disease. Surviving Mesothelioma has just posted an article ... from several Korean institutions based their mesothelioma study on the fact the Manumycin A, ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
(Date:5/18/2016)... NEW YORK , May 18, 2016 ... challenges, but it does not mean that there are no ... equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD ), Seattle ... CHMA ), and Ophthotech Corp. (NASDAQ: ... and trading alerts at: http://www.activewallst.com/ ...
(Date:5/17/2016)... Switzerland , May 18, 2016 ... GONAL-f® 2.0 prefilled pen following approval by EMA, the ... a leading science and technology company, the new pen ... bring an increased level of confidence to patients during ... new GONAL-f® prefilled pen easier to handle with a ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
Breaking Biology News(10 mins):